InnoCare confirms Mr.James Deng has accepted the invitation to be its Advisory Board Member(ABM) in Sales & Marketing

March 11, 2019, InnoCare announced that Mr. James Deng has accepted the invitation to be its ABM in Sales & Marketing,providing consultancy on launch strategy and commercial operation.

As a member of BD Global Operating Committee, Mr. James Deng is the Senior Vice President of BD and General Manager of Greater China. He is also the founding and elected AdvaMed China Board Chair for four consecutive terms.

Prior to BD, Mr. James Deng served as VP Marketing in Novartis Pharma US. Before that, he was the CEO & President for Novartis Pharma China, leading Novartis  to be the largest multinational pharmaceutical company with the fastest growing business in China. Under his leadership, the “thick product project” he initiated to optimize the company's infrastructure significantly improved the company's competitiveness. This project was selected as a classic case of Harvard Business School.

Mr. James Deng also worked for Johnson & Johnson Pharma in China. He is a graduate of China Europe International Business School (CEIBS) EMBA and General Management Program(GMP) of Harvard Business School.

Mr. James Deng now takes active role as Deputy Head of Healthcare Industry Division in China Health Economics Association.

“It’s our privilege to have Mr. James Deng to be a key member in InnoCare’s Advisory Board in Sales & Marketing.” Said Dr. Jasmine Cui, Chairman and CEO of InnoCare,” James is a highly respected leader in healthcare industry. His track-record in leading multinational pharma and MedTech companies is resulted from his profound market insights, strong business operation, and global perspective. James’ support will accelerate the pace of InnoCare’s innovative drug products reaching the patients with urgent needs”.

“I am truly honored to be a member of InnoCare’s advisory board. As someone who has been working in healthcare for 30years, I have two missions: one is always putting the patient in the center of everything we do, bringing real benefits to them; one is driving true China innovation that can make a global impact. As a leading innovative company in China, InnoCare has done an excellent job in these two aspects. I will contribute as much as I can to support InnoCare become one of the most successful organization in both drug R&D and  commercialization. I believe by doing so, together, we will greatly benefit patients in China and worldwide”.